Tag Archives: Amgen

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

After the late Rep. Elijah Cummings launched a drug pricing probe of some of the industry’s largest players last January, six pharmaceutical execs are set to head to Washington next week for hearings at the House Committee on Oversight and Reform.  Current and former executives from Celgene, Bristol Myers Squibb, Teva, Amgen, Mallinckrodt and Novartis will testify next Wednesday… Read More »

Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster

When Amgen signed an outcomes-based reimbursement deal for its blockbuster rheumatoid arthritis drug Enbrel with Harvard Pilgrim Healthcare in 2017, it seemed like a strategy for preserving the market share of a product on the cusp of losing its patent protection. The patent threat has since been pushed off several years—but Amgen is still making… Read More »